Pipeline & Technologies

Intellectual Property



GlycoVaxyn has secured exclusive, worldwide rights from the Swiss Federal Institute of Technology (ETH) to its proprietary technology (Patents 1 & 2 in Figure 5).

GlycoVaxyn is aggressively supplementing and strengthening its intellectual property position by submitting national patent applications in a number of countries. Figure 5 illustrates the company's IP portfolio.

Figure 5: GlycoVaxyn IP portfolio

Patent Title
Priority Date
Status
System and method for the production of recombinant glycosylated proteins in a prokaryotic host 3/14/2002Granted patents in JP, AU, EP, KR, SG; pending patents in CA, IL, IN and US
Recombinant N-glycosylated proteins from procaryotic cells 5/11/2005Granted patents in EP and SG, AU; pending patents in CN, CA, IL, IN, JP, KR, US
Production of a glycoconjugated shigella vaccine 2/20/2008National phase
Biosynthetic system that produces antigenic polysaccharides in prokaryotic cells 11/19/2010PCT application
Capsular Gram-Positive Bioconjugate Vaccines 5/6/2010US non-provisional / PCT application